
Amgen acquires Tularik in $1.3bn stock swap
Executive Summary
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com